Anika Therapeutics, Inc. — Director's Dealing 2021

May 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Anika Therapeutics, Inc. (ANIK)
CIK: 0000898437
Period of Report: 2021-05-18

Reporting Person: HENNEMAN JOHN B III (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-18	Common Stock	P	2000	$42.86	Acquired	11310	Direct

Footnotes

F1: On May 18, 2021, Mr. Henneman purchased 2,000 shares in multiple trades ranging from $42.63 to $42.98. The price reported above reflects the weighted average purchase price. Mr. Henneman undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected.